DelveInsight’s “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Soft Tissue Sarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Soft Tissue Sarcoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Key highlights from the Soft Tissue Sarcoma Market Report:
-
DelveInsight’s analysis forecasts significant growth in the soft tissue sarcoma market, with a robust Compound Annual Growth Rate (CAGR) expected by 2032.
-
According to updated statistics from the American Cancer Society (2022), there were approximately 13,190 new cases of soft tissue sarcoma in the US, along with around 5,130 deaths (2,740 males and 2,390 females) attributed to the disease.
-
Leading soft tissue sarcoma companies such as Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others are developing novel soft tissue sarcoma drugs that can be available in the soft tissue sarcoma market in the coming years.
-
Some of the key therapies for soft tissue sarcoma treatment include Camsirubicin, Lurbinectedin, Liposomal Annamycin (L-Annamycin), AL3818, YH001, CFT8634, Olaratumab + Doxorubicin, Tazemetostat + Doxorubicin HCl, Niraparib, Seclidemstat, Tinostamustine (EDO-S101), HFB301001, Tigilanol Tiglate, Pembrolizumab, Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy, L19TNF and DOXORUBICIN, doxorubicin with AGEN1884 and AGEN2034, APX005M, MGCD516, and others.
-
In August 2024, the Food and Drug Administration (FDA) approved a cellular therapy called afamitresgene autoleucel, or afami-cel (Tecelra), to treat some people with metastatic synovial sarcoma, a type of soft tissue sarcoma. The decision marks the first time the agency has approved a treatment called a T-cell receptor (TCR) therapy for cancer.
-
In March 2024, Lamassu awarded a grant from the NIH and NCI forthe development of their groundbreaking treatment for p53 wildtype sarcomas. The company focuses on advancing SA53, a noveltherapeutic that targets p53 wild-type sarcomas, malignant tumorsof connective or non-epithelial tissue.
-
In February 2024, Philogen provided an update on pre-plannedinterim analysis of the Phase III FIBROSARC trial investigatingOnfekafusp alfa (L19TNF) in patients with first-line advanced ormetastatic STS.
-
In Feb 2024, QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, was awarded Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) by the United States Food and Drug Administration (FDA).
Read detailed insights on Soft Tissue Sarcoma market outlook 2032 @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Soft Tissue Sarcoma Overview
Soft tissue sarcoma is a relatively uncommon cancer that develops in the body’s soft tissues, including muscles, tendons, fat, blood vessels, and nerves. While it can affect individuals of any age, it is more frequently diagnosed in adults. The precise causes of soft tissue sarcoma are not always well understood, but certain risk factors have been identified, such as exposure to radiation, specific genetic conditions, and previous treatment with certain chemotherapy drugs.
Symptoms of soft tissue sarcoma vary depending on the tumor’s location and size. Common signs include a noticeable lump or swelling in the affected area, pain or tenderness, restricted movement, and sometimes a sensation of pressure or fullness. Because these symptoms can also indicate other conditions, it is important to consult a healthcare professional if they persist or worsen.
Diagnosis typically involves a combination of imaging tests—such as MRI, CT scans, and ultrasounds—to locate and assess the tumor. A biopsy is then performed, where a small sample of tissue is taken and examined microscopically to determine whether the growth is malignant or benign.
Soft Tissue Sarcoma Epidemiology Assessment
The epidemiology section offers a comprehensive overview of historical, current, and projected epidemiological trends across the seven major markets (7MM) from 2020 to 2032. It examines various studies and research to identify the factors driving these trends. Additionally, the section includes an in-depth analysis of the diagnosed and prevalent patient populations, future trends, and perspectives from key opinion leaders.
Soft Tissue Sarcoma Epidemiology Insights:
-
In 2023, the American Cancer Society recorded roughly 13,400 new cases of STS in the United States, with 7,400 cases among males and 6,000 among females. Looking ahead to 2024, projections suggest a slight uptick, with an estimated 13,590 new cases of STS expected nationwide. Of these, approximately 7,700 cases are predicted in males and around 5,890 in females.
-
According to SEER, the rate of new cases of STS cancer was 3.4 per 100,000 men and womenper year. These rates are age-adjusted and based on 2016–2020 cases.
-
As per the Cancer Research UK (2021), about 20 out of every 100 soft tissue sarcomas in adults are liposarcomas.
Key Soft Tissue Sarcoma Therapies and Companies
-
Camsirubicin: Monopar Therapeutics
-
Lurbinectedin: Jazz Pharmaceuticals
-
Liposomal Annamycin (L-Annamycin): Moleculin Biotech, Inc.
-
AL3818: Advenchen Laboratories, LLC
-
YH001: Tracon Pharmaceuticals Inc.
-
CFT8634: C4 Therapeutics, Inc.
-
Olaratumab + Doxorubicin: Eli Lilly and Company
-
Tazemetostat + Doxorubicin HCl: Epizyme, Inc./Ipsen
-
Niraparib: GlaxoSmithKline
-
Seclidemstat: Salarius Pharmaceuticals, LLC
-
Tinostamustine (EDO-S101): Mundipharma Research Limited
-
HFB301001: HiFiBiO Therapeutics
-
Tigilanol Tiglate: QBiotics Group Limited
-
Pembrolizumab: Merck Sharp & Dohme LLC
-
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy: Polaris Group
-
L19TNF and DOXORUBICIN: Philogen S.p.A.
-
doxorubicin with AGEN1884 and AGEN2034: Agenus Inc
-
APX005M: Apexigen America, Inc.
Learn How the Soft Tissue Sarcoma Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Soft Tissue Sarcoma Treatment Market
Treatment for soft tissue sarcoma is tailored to the tumor’s type, location, stage, and the patient’s overall health. The primary approaches include surgery, radiation therapy, and chemotherapy, which may be used alone or in combination depending on the individual case.
Surgery is the main treatment for localized soft tissue sarcoma, aiming to remove the tumor along with a margin of healthy tissue to reduce the risk of recurrence. In some cases, reconstructive procedures may be necessary to preserve function and appearance.
Radiation therapy employs high-energy rays to target and destroy cancer cells or shrink tumors, either before surgery or as a standalone treatment for tumors that cannot be surgically removed. It can also be used post-surgery to lower the risk of local recurrence.
Chemotherapy is used for certain types of soft tissue sarcomas with a higher likelihood of spreading to other parts of the body. It involves drugs that kill or slow the growth of cancer cells, administered in cycles to allow the body time to recover between treatments.
Recent advancements in targeted therapies and immunotherapy offer new treatment options, particularly for cases that do not respond well to traditional methods. These innovative approaches specifically target cancer cells or stimulate the body’s immune system to combat the disease.
A multidisciplinary team, including oncologists, surgeons, radiation oncologists, and other specialists, collaborates to develop the most effective treatment plan for each patient. Ongoing follow-ups and monitoring are essential to detect any recurrence or side effects. While treating soft tissue sarcoma presents challenges, continued research and personalized treatment strategies provide hope for improved outcomes and a better quality of life for those affected.
Leading Players in the Soft Tissue Sarcoma Therapeutics Market Include:
Soft Tissue Sarcoma Companies working in the market are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Soft Tissue Sarcoma Report Covers the In-depth Assessment of the Emerging Soft Tissue Sarcoma Drugs & Key Companies. Download the Soft Tissue Sarcoma Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Key Insights
2. Executive Summary
3. Soft Tissue Sarcoma Competitive Intelligence Analysis
4. Soft Tissue Sarcoma Market Overview at a Glance
5. Soft Tissue Sarcoma Disease Background and Overview
6. Soft Tissue Sarcoma Patient Journey
7. Soft Tissue Sarcoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Soft Tissue Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Soft Tissue Sarcoma Unmet Needs
10. Key Endpoints of Soft Tissue Sarcoma Treatment
11. Soft Tissue Sarcoma Marketed Products
12. Soft Tissue Sarcoma Emerging Drugs and Latest Therapeutic Advances
13. Soft Tissue Sarcoma Seven Major Market Analysis
14. Attribute Analysis
15. Soft Tissue Sarcoma Market Outlook (In US, EU5, and Japan)
16. Soft Tissue Sarcoma Access and Reimbursement Overview
17. KOL Views on the Soft Tissue Sarcoma Market
18. Soft Tissue Sarcoma Market Drivers
19. Soft Tissue Sarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/